Background: It is important to use vascular imaging modalities such as CT, MRI and PET-CT to evaluate disease activity of Takayasu arteritis (TAK). In particular, under treatment with tocilizumab (TCZ), residual vasculitic disease activity may remain even if serum CRP becomes negative. Contrast-enhanced CT,MRI and PET-CT can evaluate the morphology of blood vessel walls and the distribution of lesions and vasculitic activity, but it is invasive (radiation or contract media exposure), and costly. Ultrasound is superior in terms of morphological evaluation, cost, convenience, and low invasiveness. In particular, Superb Micro-vascular Imaging(SMI) is one of the micro blood flow display methods that can be installed in the ultrasound diagnostic device Aplio series.

There are some case reports in which micro blood flow signals of the carotid artery walls were detected using SMI in Takayasu arteritis [1][2]. Both reports indicate that SMI blood flow is a comparable indicator of disease activity as serum CRP.

Objectives: To report the usefulness of SMI in 2 TAK patients who had negative serum CRP but had residual disease activity, leading to appropriate adjustment of treatment.

Methods: Two TAK patients who had been newly diagnosed in our department from May 2015 to October 2018 and had received SMI to detect carotid artery wall blood flow signal were retrospectively analyzed.

Results: Case 1
A 32-year-old woman developed neck pain, headaches, fever and she had high serum levels of CRP (8.1 mg/dl) but had micro blood flow signal in carotid artery wall. Diagnosis of TAK was made. After 2-week treatment with 1 mg/kg/day of PSL, CRP became negative but the micro blood flow in carotid artery walls was detected by SMI. Therefore, subcutaneous TCZ (162 mg/wk) was added in combination with PSL. One year later, micro blood flow disappeared and we could judge there was no vasculitis activity (Figure A).

Case 2
A 17-year-old woman developed proximal upper limb pain and fever with high serum CRP levels (7.1 mg/dl) and elevated ESR (>110 mm/h), and contrast-enhanced CT showed thickening of the carotid arteries and aortic arch. Two weeks after the start of PSL (1 mg/kg/day), CRP became negative at 0.3 mg/dl, but intramural blood flow detected by SMI remained. Then subcutaneous TCZ was added. Two weeks later, CRP became negative, and the SMI blood flow also disappeared (Figure B).

<table>
<thead>
<tr>
<th>Before treatment</th>
<th>2 weeks after starting treatment</th>
<th>One year after starting treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>treatment</td>
<td>PSL 1 mg/kg/day ongoing</td>
<td>PSL 1 mg/kg/day ongoing</td>
</tr>
<tr>
<td>CRP (mg/dl)</td>
<td>+ (8.1)</td>
<td>+ (0.0)</td>
</tr>
<tr>
<td>SMI signal</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

Figure 1. A. Clinical course of Case 1

Figure 2. B. Clinical course of Case 2

Conclusion: Although SMI has the limitation that it cannot evaluate deep vascular lesions such as aorta, it is neither invasive nor costly and may be a good tool for evaluation of residual vasculitis activity of TAK.

References:

Acknowledgments: We thank Minako.Yamashita and Masahiro.setoyama for her technical assistance to conduct SMI.

Disclose of Interests: None declared

ABT125 PERFORMANCE OF ULTRASOUND TO ASSESS EROSION PROGRESSION IN RHEUMATOID ARTHRITIS

M. Faras1, E. Alladio1, E. Albujaass1, M. Coudev2, P. Ometti1, C. Roux3, J. Grosse1, I. C. Valckenbeeke1, D. Loeuille1, CHRU Nancy, Nancy, France; CHU Gabriel-Montpied, Clermont-Ferrand, France; CHU Dijon Bourgogne, Dijon, France; HPM Belle Isle, Metz, France

Background: Ultrasonography (US) can detect more erosions than radiography (RX) at the joint level in rheumatoid arthritis (RA), especially at an early stage of the disease.

Objectives: The aim of the study is to determine the ability of ultrasonography to detect erosion progression by the US Score for erosions (USSe), in early (less than 2 years disease duration (DD)) and late stage (more than 2 years DD) RA over two years of follow-up.

Methods: Patients fulfilling ACR 1987 and/or ACR/EULAR 2010 criteria for RA were prospectively included. Clinical and demographic informations were recorded at baseline and hands and feet RX were scored according to the Sharp erosion score (SHSe). Erosive RA on RX was defined by the presence of at least three eroded joints (1). US examinations were performed at baseline and during the two years of follow-up. Erosions were scored by US on six bilateral joints (MCP 2, 3, 5 and MTP 2, 3, 5) with a four grade-scale to calculate total USSe. Erosive RA on US was defined by presence of one erosion ≥ 2 mm; inter-examiner reproducibility was performed on 14 patients in order to calculate the smallest detectable change (SDC), which was 2.3. Ultrasonographic progression was defined as a change in USSe > 2 (erosion change > SDC).

Results: A total of 71 patients were included, 22 patients (31.0%) had early RA and 49 (69.0%) patients had late RA diseases. On RX, 30 (42.3%) patients were erosive at baseline with a mean SHSe at 29.4 (SD at 24.7).

Before treatment | 2 weeks after starting treatment | 4 weeks after starting treatment |
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>treatment</td>
<td>PSL 1 mg/kg/day ongoing</td>
<td>PSL 50 mg/kg/day ongoing</td>
</tr>
<tr>
<td>CRP (mg/dl)</td>
<td>+ (0.3)</td>
<td>+ (0.0)</td>
</tr>
<tr>
<td>SMI signal</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

DOI: 10.1136/annrheumdis-2020-eular.1806